Wire flash
Fosun Pharma unit gets exclusive license to develop two T-cell engager products
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
On September 23, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) announced that its subsidiary, Henlius, has entered into a Collaboration and License Agreement with Amberstone. Under the agreement, Henlius obtains an exclusive global license to research, develop, manufacture, and commercialize two T-cell engager (TCE) products targeting specific tumor antigens, using Amberstone's proprietary T-MATE™ technology platform. The T-MATE™ platform is a tumor microenvironment-activated technology designed to enhance the selective targeting of TCE molecules to tumor tissues while reducing effects on normal tissues, potentially addressing the narrow therapeutic window and safety limitations of traditional TCE products in solid tumor treatment. The collaboration focuses on two targets designated by Henlius for oncology applications.
Source report
Shanghai, September 23 — Fosun Pharma (600196.SH) announced today that its controlling subsidiary, Henlius, has entered into a Cooperation and License Agreement with Amberstone on September 23, 2026.
Under the terms of the agreement, Amberstone grants Henlius an exclusive license for the research, development, production, and commercialization of two collaboration products—T Cell Engager (TCE) products—targeting designated targets. The license covers all human therapeutic indications globally and is based on Amberstone's proprietary T-MATE™ technology platform.
Collaboration Details
- The two parties will leverage the T-MATE™ platform to design and develop T Cell Engager (TCE) products for oncology treatment, targeting two specific targets designated by Henlius.
- The T-MATE™ platform is Amberstone's proprietary tumor microenvironment-activated technology platform.
- It modulates the activation state of TCE molecules in both the tumor microenvironment and peripheral tissues, enhancing selective targeting of tumor tissues while reducing potential impact on normal tissues.
Potential Advantages
The technology is expected to address key limitations of traditional TCE products in solid tumor treatment, including:
- Narrow therapeutic window
- Limited safety profile
Source
格隆汇Neutral / independent
Part of this Story
Fosun Pharma unit Henlius secures global license for two T-cell engager products from Amberstone